The cancer vaccine that even its own inventors didn't believe in
At an off-site leadership meeting in March 2023, Moderna CEO Stéphane Bancel asked the roughly 100 executives in the room to stand up if they'd actually expected their experimental cancer vaccine to work.
Company president Stephen Hoge was standing on stage. He sat back down. So did Bancel 13. That's how uncertain this looked, even from the inside. Last week, Moderna and Merck announced that a 1,137-volunteer trial of the vaccine, called intismeran autogene, showed it reduced the odds that surgically removed melanoma would return or spread 13. The vaccine is built individually for each patient and can be tailored to target up to 34 different mutations in that person's specific tumor 46, which is the part that makes this a personalized medicine story as much as a cancer story: the shot itself is different for every person who receives it.
What each field noticed (2)
Inside Moderna and Merck's cancer vaccine triumph
STAT's account is really about disbelief turning into evidence, tracking how a technology many doubted, including some of the people who built it, kept clearing hurdles nobody expected it to clear, from skeptical investors betting against Moderna's stock to skeptics of mRNA itself 13.
Read the storyWorld's first personalized mRNA cancer vaccine succeeds in US Phase 3 trial
The technology write-up skips the boardroom drama and goes straight to the engineering: a single vaccine platform flexible enough to be re-coded for up to 34 mutations per patient, a level of personalization that wasn't practical at this scale before 46.